Scalper1 News
Generic-drug giant Mylan (MYL) late Monday reported Q4 earnings and 2015 guidance in line with Wall Street’s expectations, shortly after closing a major buyout. Mylan’s profit rose 35% over the year-earlier quarter to $1.05 a share, exactly as analysts expected, according to Thomson Reuters. Revenue gained 15% to $2.08 billion, slightly above consensus of $2.07 billion. Still, Mylan stock was down nearly 2% in after-hours trading Monday, after the Scalper1 News
Scalper1 News